Cross-sectoral and international collaborations are the key to drive innovation in healthcare related life sciences R&D. To strengthen the Flemish position in the field of immunology, infectious diseases and vaccinology, Flanders vaccine aims to build a strong community.
Flanders vaccine is a consortium set up to stimulate innovation in vaccine related research and business, by catalyzing public-private partnerships. Moreover, this new initiative will define and implement strategic roadmaps within the domain of immunology, infectious diseases and vaccinology resulting in a vivid transfer of knowledge, expertise and complementary innovative technologies boosting the dynamic academic and industrial landscape.
Piet Stinissen, UHasselt
12:20 Official launch Flanders Vaccine
Jo Vandeurzen, Flemish Minister for Welfare, Public Health and Family
12:35 Introduction Flanders Vaccine: building Partnerships in vaccine-related R&D
Wendy Hansen, Flanders Vaccine
12:50 Vaccines at the FAMHP: becoming a point of reference
Greet Musch, Federal Agency for Medicines and Health Products (FAMHP/FAGG)
14:00 KEYNOTE: Novel generations of influenza vaccines
Marc Van Ranst, UZ Leuven & KU Leuven
14:20 Vaccine trials in humans: the role vaccine centers can play
Pierre Van Damme, UAntwerpen & Isabel Leroux-Roels, UGent
14:35 Why is a big industrial player in infectious diseases and vaccines interested in intense collaboration with academic vaccine specialists & biotech companies?
Johan Van Hoof, Janssen Pharmaceuticals
14:50 An SME in human healthcare: Developing disease modifying immunotherapies for autoimmune and allergic diseases
Lotta Jansson, Apitope
15:05 An SME in animal healthcare
Chris Cardon, Ecuphar
15:20 Health, Science and Technology (HST): Industrial pharma presence in Belgium
Christian De La Porte, Health, Science and Technology (HST) group
15:35 Network reception